B cell inhibitory receptors and autoimmunity

Immunology

Volumn 108, Issue 3, 2003, Pages 263-273

  Pritchard, Nicholas R ^a   Smith, Kenneth G C ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; CD22 ANTIGEN; CD5 ANTIGEN; CD72 ANTIGEN; FC RECEPTOR; INTERLEUKIN 2; MEMBRANE PROTEIN; PROTEIN PD 1; UNCLASSIFIED DRUG;

ASTHMA; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; CROHN DISEASE; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; INSULIN DEPENDENT DIABETES MELLITUS; KNOCKOUT MOUSE; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD22; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; ANTIGENS, SURFACE; APOPTOSIS REGULATORY PROTEINS; AUTOIMMUNITY; B-LYMPHOCYTES; CELL ADHESION MOLECULES; HUMANS; LECTINS; MICE; RECEPTORS, ANTIGEN, B-CELL; RECEPTORS, IGG; SELF TOLERANCE;

EID: 0037342154     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.2003.01592.x     Document Type: Review

References (95)

1. Muta T, Kurosaki T, Misulovin Z, Sanchez M, Nussenzweig MC, Ravetch JV. A 13-amino-acid motif in the cytoplasmic domain of Fc gamma RIIB modulates B-cell receptor signalling. Nature 1994; 368:70-3.
2. Doody GM, Justement LB, Delibrias CC, Matthews RJ, Lin J, Thomas ML, Fearon DT. A role in B cell activation for CD22 and the protein tyrosine phosphatase SHP. Science 1995; 269:242-4.
3. Smith KGC, Tarlinton DM, Doody GM, Hibbs ML, Fearon DT. Inhibition of the B cell by CD22: a requirement for Lyn. J Exp Med 1998; 187:807-11.
4. Tamir I, Dal Porto IM, Cambier JC. Cytoplasmic protein tyrosine phosphatases SHP-1 and SHP-2: regulators of B cell signal transduction. Curr Opin Immunol 2000; 12:307-15.
5. Daeron M. Fc receptor biology. Annu Rev Immunol 1997; 15:203-34.
6. Malbec O, Fridman WH, Daeron M. Negative regulation of hematopoietic cell activation and proliferation by Fc gamma RIIB. Curr Top Microbiol Immunol 1999; 244:13-27.
7. Brooks DG, Qiu WQ, Luster AD, Ravetch JV. Structure and expression of human IgG FcRII (CD32). Functional heterogeneity is encoded by the alternatively spliced products of multiple genes. J Exp Med 1989; 170:1369-85.
8. Latour S, Fridman WH, Daeron M. Identification, molecular cloning, biologic properties, and tissue distribution of a novel isoform of murine low-affinity IgG receptor homologous to human Fc gamma RIIB 1. J Immunol 1996; 157:189-97.
9. Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol 2001; 19:275-90.
10. Takai T, Ono M, Hikida M, Ohmori H, Ravetch JV. Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice. Nature 1996; 379:346-9.
11. Yuasa T, Kubo S, Yoshino T, Ujike A, Matsumura K, Ono M, Ravetch JV, Takai T. Deletion of fcgamma receptor IIB renders H-2(b) mice susceptible to collagen-induced arthritis. J Exp Med 1999; 189:187-94.
12. Nakamura A, Yuasa T, Ujike A, Ono M, Nukiwa T, Ravetch JV, Takai T. Fcgamma receptor IIB-deficient mice develop Goodpasture's syndrome upon immunization with type IV collagen: a novel murine model for autoimmune glomerular basement membrane disease. J Exp Med 2000; 191:899-906.
13. Bolland S, Ravetch JV. Spontaneous autoimmune disease in Fc (gamma) RIIB-deficient mice results from strain-specific epistasis. Immunity 2000; 13:277-85.
14. Boackle SA, Holers VM, Chen X, Szakonyi G, Karp DR, Wakeland EK. Morel L. Cr2, a candidate gene in the murine Sle1c lupus susceptibility locus, encodes a dysfunctional protein. Immunity 2001; 15:775-85.
15. Morel L, Blenman KR, Croker BP, Wakeland EK. The major murine systemic lupus erythematosus susceptibility locus, Sle1, is a cluster of functionally related genes. Proc Natl Acad Sci USA 2001; 98:1787-92.
16. Pritchard NR, Cutler AJ, Uribe S, Chadban SJ, Morley BJ, Smith KGC. Autoimmune-prone mice share a promoter haplotype associated with reduced expression and function of the Fc receptor FcgammaRII. Curr Biol 2000; 10:227-30.
17. Jiang Y, Hirose S, Sanokawa-Akakura R et al. Genetically determined aberrant down-regulation of FcgammaRIIB1 in germinal center B cells associated with hyper-IgG and IgG autoantibodies in murine systemic lupus erythematosus. Int Immunol 1999; 11:1685-91.
18. Luan JJ, Monteiro RC, Sautes C, Fluteau G, Eloy L, Fridman WH, Bach JF, Garchon HJ. Defective Fc gamma RII gene expression in macrophages of NOD mice: genetic linkage with up-regulation of IgG1 and IgG2b in serum. J Immunol 1996; 157:4707-16.
19. Xiu Y, Nakamura K, Abe M et al. Transcriptional regulation of Fcgr2b gene by polymorphic promoter region and its contribution to humoral immune responses. J Immunol 2002; 169:4340-6.
20. Bolland S, Yim Y, Tus K, Wakeland E, Ravetch J. Genetic modifiers of systemic lupus erythematosus in FcgammaRIIB (-/-) mice. J Exp Med 2002; 195:1167-74.
21. Hashimoto L, Habita C, Beressi JP et al. Genetic mapping of a susceptibility locus for insulin-dependent diabetes mellitus on chromosome 11q. Nature 1994; 371:161-4.
22. Shai R, Quismorio FP Jr, Li L et al. Genome-wide screen for systemic lupus erythematosus susceptibility genes in multiplex families. Hum Mol Genet 1999; 8:639-44.
23. Gaffney PM, Kearns GM, Shark KB et al. A genome-wide search for susceptibility genes in human systemic lupus erythematosus sib-pair families. Proc Natl Acad Sci USA 1998; 95:14875-9.
24. Gaffney PM, Ortmann WA, Selby SA et al. Genome screening in human systemic lupus erythematosus results from a second Minnesota cohort and combined analyses of 187 sib-pair families. Am J Hum Genet 2000; 66:547-56.
25. Harley JB, Moser KL, Gaffney PM, Behrens TW. The genetics of human systemic lupus erythematosus. Curr Opin Immunol 1998; 10:690-6.
26. Wakeland EK, Liu K, Graham RR, Behrens TW. Delineating the genetic basis of systemic lupus erythematosus. Immunity 2001; 15:397-408.
27. Botto M, Theodoridis E, Thompson EM, Beynon HL, Briggs D, Isenberg DA, Walport MJ, Davies KA. Fc gamma RIIa polymorphism in systemic lupus erythematosus (SLE): no association with disease. Clin Exp Immunol 1996; 104:264-8.
28. Kyogoku C, Dijstelbloem H, Tsuchiya N et al. Fcγ receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus. Arthritis Rheum 2002; 46:1242-54.
29. Dorken B, Moldenhauer G, Pezzutto A, Schwartz R, Feller A, Kiesel S, Nadler LM. HD39 (B3), a B lineage-restricted antigen whose cell surface expression is limited to resting and activated human B lymphocytes. J Immunol 1986; 136:4470-9.
30. Smith KGC, Fearon DT. Receptor modulators of BCR signalling - CD19/22. Curr Top Microbiol Immunol 1999; 245:195-212.
31. Hanasaki K, Varki A, Stamenkovic I, Bevilacqua MP. Cytokine-induced beta-galactoside alpha-2,6-sialyltransferase in human endothelial cells mediates alpha 2,6-sialylation of adhesion molecules and CD22 ligands. J Biol Chem 1994; 269:10637-43.
32. Neuberger MS, Lanoue A, Ehrenstein MR, Batista FD, Sale JE, Williams GT. Antibody diversification and selection in the mature B-cell compartment. Cold Spring Harb Symp Quant Biol 1999; 64:211-16.
33. O'Keefe TL, Williams GT, Davies SL, Neuberger MS. Hyperresponsive B cells in CD22-deficient mice. Science 1996; 274:798-801.
34. O'Keefe TL, Williams GT, Batista FD, Neuberger MS. Deficiency in CD22, a B cell-specific inhibitory receptor, is sufficient to predispose to development of high affinity autoantibodies. J Exp Med 1999; 189:1307-13.
35. Mary C, Laporte C, Parzy D et al. Dysregulated expression of the Cd22 gene as a result of a short interspersed nucleotide element insertion in Cd22a lupus-prone mice. J Immunol 2000; 165:2987-96.
36. Cornall RJ, Cyster JG, Hibbs ML, Dunn AR, Otipoby KL, Clark EA, Goodnow CC. Polygenic autoimmune traits. Lyn, CD22, and SHP-1 are limiting elements of a biochemical pathway regulating BCR signalling and selection. Immunity 1998; 8:497-508.
37. Kono DH, Burlingame RW, Owens DG, Kuramochi A, Balderas RS, Balomenos D, Theofilopoulos AN. Lupus susceptibility loci in New Zealand mice. Proc Natl Acad Sci USA 1994; 91:10168-72.
38. Morel L, Rudofsky UH, Longmate JA, Schiffenbauer J, Wakeland EK. Polygenic control of susceptibility to murine systemic lupus erythematosus. Immunity 1994; 1:219-29.
39. Morel L, Mohan C, Yu Y, Croker BP, Tian N, Deng A, Wakeland EK. Functional dissection of systemic lupus erythematosus using congenic mouse strains. J Immunol 1997; 158:6019-28.
40. Ghosh S, Palmer SM, Rodrigues NR et al. Polygenic control of autoimmune diabetes in nonobese diabetic mice. Nat Genet 1993; 4:404-9.
41. Butterfield RJ, Blankenhorn EP, Roper RJ et al. Genetic analysis of disease subtypes and sexual dimorphisms in mouse experimental allergic encephalomyelitis (EAE): relapsing/remitting and monophasic remitting/nonrelapsing EAE are immunogenetically distinct. J Immunol 1999; 162:3096-102.
42. Baker D, Rosenwasser OA, O'Neill JK, Turk JL. Genetic analysis of experimental allergic encephalomyelitis in mice. J Immunol 1995; 155:4046-51.
43. Davies JL, Kawaguchi Y, Bennett ST et al. A genome-wide search for human type 1 diabetes susceptibility genes. Nature 1994; 371:130-6.
44. Sawcer S, Jones HB, Feakes R et al. A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22. Nat Genet 1996; 13:464-8.
45. Haines JL, Ter-Minassian M, Bazyk A et al. A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex. The Multiple Sclerosis Genetics Group. Nat Genet 1996; 13:469-71.
46. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. Embo J 1992; 11:3887-95.
47. Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H, Honjo T. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 1996; 8:765-72.
48. Freeman GJ, Long AJ, Iwai Y et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192:1027-34.
49. Latchman Y, Wood CR, Chernova T et al. PD-L2 is a second ligand for PD-I and inhibits T cell activation. Nat Immunol 2001; 2:261-8.
50. Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T. PD-1 immunoreceptor inhibits B cell receptor-mediated signalling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci USA 2001; 98:13866-7.
51. Nishimura H, Honjo T. PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol 2001; 22:265-8.
52. Nishimura H, Minato N, Nakano T, Honjo T. Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses. Int Immunol 1998; 10:1563-72.
53. Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999; 11:141-51.
54. Nishimura H, Okazaki T, Tanaka Y et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 2001; 291:319-22.
55. Nishimura H, Honjo T, Minato N. Facilitation of beta selection and modification of positive selection in the thymus of PD-1-deficient mice. J Exp Med 2000; 191:891-8.
56. Moser KL, Neas BR, Salmon JE et al. Genome scan of human systemic lupus erythematosus: evidence for linkage on chromosome 1q in African-American pedigrees. Proc Natl Acad Sci USA 1998; 95:14869-74.
57. Bolen JB, Rowley RB, Spana C, Tsygankov AY. The Src family of tyrosine protein kinases in hemopoietic signal transduction. Faseb J 1992; 6:3403-9.
58. Burkhardt AL, Brunswick M, Bolen JB, Mond JJ. Anti-immunoglobulin stimulation of B lymphocytes activates src-related protein-tyrosine kinases. Proc Natl Acad Sci USA 1991; 88:7410-14.
59. + mobilization through distinct pathways. EMBO J 1994; 13:1341-9.
60. Malbec O, Fong DC, Turner M, Tybulewicz VL, Cambier JC, Fridman WH, Daeron M. Fc epsilon receptor I-associated lyn-dependent phosphorylation of Fc gamma receptor IIB during negative regulation of mast cell activation. J Immunol 1998; 160:1647-58.
61. Wang J, Koizumi T, Watanabe T. Altered antigen receptor signalling and impaired Fas-mediated apoptosis of B cells in Lyn-deficient mice. J Exp Med 1996; 184:831-8.
62. Hibbs ML, Tarlinton DM, Armes J, Grail D, Hodgson G, Maglitto R, Stacker SA, Dunn AR. Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease. Cell 1995; 83:301-11.
63. Huck S, Le Corre R, Youinou P, Zouali M. Expression of B cell receptor-associated signalling molecules in human lupus. Autoimmunity 2001; 33:213-24.
64. Liossis SN, Solomou EE, Dimopoulos MA, Panayiotidis P, Mavrikakis MM, Sfikakis PP. B-cell kinase lyn deficiency in patients with systemic lupus erythematosus. J Invest Med 2001; 49:157-65.
65. Hof P, Pluskey S, Dhe-Paganon S, Eck MJ, Shoelson SE. Crystal structure of the tyrosine phosphatase SHP-2. Cell 1998; 92:441-50.
66. Barford D, Neel BG. Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2. Structure 1998; 6:249-54.
67. Vely F, Olivero S, Olcese L et al. Differential association of phosphatases with hematopoietic co-receptors bearing immunoreceptor tyrosine-based inhibition motifs. Eur J Immunol 1997; 27:1994-2000.
68. Huyer G, Alexander DR. Immune signalling: SHP-2 docks at multiple ports. Curr Biol 1999; 9:R129-32.
69. Boltand S, Ravetch JV. Inhibitory pathways triggered by ITIM-containing receptors. Adv Immunol 1999; 72:149-77.
70. Green MC, Shultz LD. Motheaten, an immunodeficient mutant of the mouse. 1. Genetics and pathology. J Hered 1975; 66:250-8.
71. Shultz LD, Coman DR, Bailey CL, Beamer WG, Sidman CL. 'Viable motheaten'; a new allele at the motheaten locus. I. Pathology. Am J Pathol 1984; 116:179-92.
72. Tsui HW, Siminovitch KA, de Souza L, Tsui FW. Motheaten and viable motheaten mice have mutations in the haematopoietic cell phosphatase gene. Nat Genet 1993; 4:124-9.
73. + B cells in viable motheaten and normal mice. Science 1986; 232:1423-5.
74. YuCC, Tsui HW, Ngan BY, Shulman MJ, Wu GE, Tsui FW. B and T cells are not required for the viable motheaten phenotype. J Exp Med 1996; 183:371-80.
75. McIndoe RA, Bohlman B, Chi E, Schuster E, Lindhardt M, Hood L. Localization of non-MHC collagen-induced arthritis susceptibility loci in DBA/1j mice. Proc Natl Acad Sci USA 1999; 96:2210-14.
76. Melanitou E, Joly F, Lathrop M, Boitard C, Avner P. Evidence for the presence of insulin-dependent diabetes-associated alleles on the distal part of mouse chromosome 6. Genome Res 1998; 8:608-20.
77. Lioubin MN, Algate PA, Tsai S, Carlberg K, Aebersold A, Rohrschneider LR. p150Ship, a signal transduction molecule with inositol polyphosphate-5-phosphatase activity. Genes Dev 1996; 10:1084-95.
78. Kavanaugh W, Pot D, Chin S et al. Multiple forms of an inositol polyphosphate 5-phosphatase form signalling complexes with Shc and Grb2. Curr Biol 1996; 6:438-45.
79. Huber M, Helgason C, Damen J et al. The role of SHIP in growth factor induced signalling. Prog Biophys Mol Biol 1999; 71:423-4.
80. Damen J, Liu L, Rosten P, Humphries R, Jefferson A, Majerus P, Krystal G. The 145-kDa protein induced to associate with Shc by multiple cytokines is an inositol tetraphosphate and phosphatidylinositol 3,4,5-triphosphate 5-phosphatase. Proc Natl Acad Sci USA 1996; 93:1689-93.
81. Brauweiler AM, Tamir I, Cambier JC. Bilevel control of B-cell activation by the inositol 5-phosphatase SHIP. Immunol Rev 2000; 176:69-74.
82. Helgason CD, Damen JE, Rosten P et al. Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span. Genes Dev 1998; 12:1610-20.
83. Liu Q, Oliveira-Dos-Santos AJ, Mariathasan S et al. The inositol polyphosphate 5-phosphatase ship is a crucial negative regulator of B cell antigen receptor signalling. J Exp Med 1998; 188:1333-42.
84. Helgason CD, Kalberer CP, Damen JE, Chappel SM, Pineault N, Krystal G, Humphries RK. A dual role for Src homology 2 domain-containing inositol-5-phosphatase (SHIP) in immunity aberrant development and enhanced function of B lymphocytes in ship -/- mice. J Exp Med 2000; 191:781-94.
85. Luo D, Maclaren N, Huang H, Muir A, She J. Intrafamilial and case-control association analysis of D2S152 in insulin-dependent diabetes. Autoimmunity 1995; 2:143-7.
86. Rudge EU, Cutler AJ, Pritchard NR, Smith KGC. Interleukin 4 reduces expression of inhibitory receptors on B cells and abolishes CD22 and Fc gamma RII-mediated B cell suppression. J Exp Med 2002; 195:1079-85.
87. Erb KJ, Ruger B, von Brevern M, Ryffel B, Schimpl A, Rivett K. Constitutive expression of interleukin (IL)-4 in vivo causes autoimmune-type disorders in mice. J Exp Med 1997; 185:329-39.
88. Drake CG, Rozzo SJ, Hirschfeld HF, Smarnworawong NP, Palmer E, Kotzin BL. Analysis of the New Zealand Black contribution to lupus-like renal disease. Multiple genes that operate in a threshold manner. J Immunol 1995; 154:2441-7.
89. Hogarth MB, Slingsby JH, Allen PJ et al. Multiple lupus susceptibility loci map to chromosome 1 in BXSB mice. J Immunol 1998; 161:2753-61.
90. Jordan MA, Silveira PA, Shepherd DP et al. Linkage analysis of systemic lupus erythematosus induced in diabetes-prone nonobese diabetic mice by Mycobacterium bovis. J Immunol 2000; 165:1673-84.
91. Johansson AC, Sundler M, Kjellen P et al. Genetic control of collagen-induced arthritis in a cross with NOD and C57BL/10 mice is dependent on gene regions encoding complement factor 5 and FcgammaRIIb and is not associated with loci controlling diabetes. Eur J Immunol 2001; 31:1847-56.
92. Gray-McGuire C, Moser KL, Gaffney PM et al. Genome scan of human systemic lupus erythematosus by regression modeling: evidence of linkage and epistasis at 4p 16-15.2. Am J Hum Genet 2000; 67:1460-9.
93. Daniels SE, Bhattacharrya S, James A et al. A genome-wide search for quantitative trait loci underlying asthma. Nature 1996; 383:247-50.
94. Field LL, Tobias R, Magnus T. A locus on chromosome 15q26 (IDDM3) produces susceptibility to insulin-dependent diabetes mellitus. Nat Genet 1994; 8:189-94.
95. Ebers GC, Kukay K, Bulman DE et al. A full genome search in multiple sclerosis. Nat Genet 1996; 13:472-6.